12,000 broncho-aspirate. 2 Broncho-aspiration of gastric juice may lead to acute respiratory distress 57 syndrome, 3 carrying a 40% mortality rate. 4 The risk is increased 10-fold in patients undergoing 58 emergency surgery. 5 Trauma patients may have ingested food before their accident, or have swallowed 59 blood from oral or nasal injuries. Also, gastric emptying is delayed due to head injury, stress, pain, and 60 opioid medication. [6] [7] [8] [9] Non-trauma patients may have delayed gastric emptying due to paralytic ileus, 61 critical illness, or cytokine release, leading to significant residual stomach content even after long 62 fasting periods. 10,11 63
Strategies have been proposed to decrease the risk of broncho-aspiration. The efficacy and safety of 64 digital pressure on the cricoid cartilage to occlude the upper esophagus during tracheal intubation, 12 65 have been challenged. 13 As non-acid gastric liquid is considered less deleterious, 14,15 pre-medication 66 with antacids, H2-receptor antagonists, or proton pump inhibitors have been advocated. 15, 16 Another 67 approach would be to facilitate gastric emptying or drainage. Clearly, a patient with an entirely empty 68 stomach cannot regurgitate and broncho-aspirate. Stomach drainage with a gastric tube 17 does not 69 guarantee complete emptying. Also, preoperative insertion of a gastric tube in a non-sedated patient is 70 not without hazards, 18 and is only recommended in patients with bowel obstruction. An alternative 71 would be to administer a pro-kinetic drug before induction of anesthesia. 19 Erythromycin, a macrolide 72 antibiotic, and motilin receptor agonist induces antral contractions, 20-22 and increases the lower 73 esophageal sphincter tone, [23] [24] [25] [26] which is an important barrier against gastro-esophageal reflux. 27 
74
Although gastric emptying properties of erythromycin have been confirmed in various settings, 28-36 its 75 efficacy in patients undergoing emergency surgery has never been investigated. 76
We aimed to investigate whether erythromycin clears the stomach of patients undergoing general 77 anesthesia for emergency surgery.
Study design 80
This study was a single center, randomized, placebo-controlled, double-blinded trial, stratified into 81 trauma related surgery and surgery for medical reasons -for instance, acute abdomen. The protocol 82 was approved by the Institutional Ethics Committee (protocol N° NAC 06-225) and the Swiss agency 83 for therapeutic products (SWISSMEDIC, 2008 DR 2321), was inspected by SWISSMEDIC, and 84 monitored by the Clinical Trials Centre of Geneva University Hospitals. Written informed consent 85 was obtained from all patients. 86
Patients

87
Adult patients, requiring general anesthesia for emergency surgery were eligibile. Exclusion criteria 88
were American Society of Anesthesiology status > III; allergy to erythromycin; concomitant use of 89 drugs interfering with erythromycin metabolism (for instance, terfenadine); intermittent porphyria; 90 severe liver or renal disease; severe asthma, exacerbated chronic obstructive lung disease, or acute 91 pulmonary infection; acute coronary heart disease, decompensated cardiac insufficiency, or aortic 92 aneurysm; esophageal and pharyngeal disease; status after gastric surgery; need for an immediate 93 surgical intervention; Glasgow Coma Scale <13; inability to understand the study protocol; obstructive 94 ileus; gastric tube; and pregnant or breast feeding women. 95
Randomization and masking
96
Hospital pharmacy performed randomization (ratio 1:1) and prepared study medications in numbered 97 10 ml syringes of erythromycin 3% and matching placebo (physiological saline). The content of a 98 syringe was added to 90 ml physiological saline. Of this solution, 1 ml per kg bodyweight was 99 administered intravenously over five minutes (corresponding to 3 mg kg -1 of erythromycin). 36 100
Allocation sequence was concealed until study end.
Procedures
102
Unpremedicated patients were randomized to the study drugs upon arrival in the operating room. 103
Fifteen minutes after drug administration, patients were pre-oxygenated during three minutes. General 104 anesthesia was induced with a classic rapid sequence procedure, 37,38 and maintained at the discretion 105 of the attending anesthetist. Immediately after intubation, one of three senior gastroenterologists (JLF, 106 LS, EG) performed an endoscopy (Endoscope GIF, Olympus, Hamburg, Germany) for qualitative and 107 quantitative assessment of gastric content. The working channel of the endoscope (inner diameter, 9 108 mm) was used to aspirate gastric liquid. The volume of the aspirate was quantified using a ml-graded 109 recipient and when gastric content could not be aspirated (solid food, mixture of liquid and food), it 110 was visually estimated (the opened forceps of the endoscope measures 7 mm in diameter; the volume 111 of solid food was estimated as a multiple of this diameter). 112
Outcomes 113
As there was no consistent definition of what should be considered clear stomach in surgical 114 patients, 39 we defined clear stomach as a residual volume of <40 ml and absence of solid food. We 115 performed a sensitivity analysis using "no liquid and no solid" as an alternative, more stringent, 116 definition of clear stomach. The secondary endpoint was the acidity (pH indicator strips 0-14, Merck, 117 Darmstadt, Germany) of residual stomach contents. Additional endpoints were volume and 118 composition of residual gastric content (liquid only, solid only, mixture of liquid and solid), delay 119 between last oral intake and time of endoscopy, and preoperative opioid and antacid medication. In 120 trauma patients, an Injury Severity Score was computed. 40 In non-trauma patients, the diagnosis was 121 recorded. As emergency patients are likely to have stress-induced hyperglycemia, which may reduce 122 erythromycin-induced acceleration of gastric emptying, 41 blood glucose was measured (Contour blood 123 glucose meter, Bayer, Zürich, Switzerland). 124
Safety endpoints included pre-induction arrhythmia, 42 stomach cramps, and nausea or vomiting. 125
Patients were visited 24 hours after study drug administration and monitored for any adverse effects 126 that could have occurred in relation with the study.
Based on a trial that evaluated the efficacy of erythromycin in patients with gastrointestinal bleeding, 129 36 we assumed a baseline incidence of 30% clear stomach with placebo, and expected that 130 erythromycin would increase this proportion to 80% (absolute risk difference, 50%). A sample of 20 131 patients per group was required (90% power, two-sided test, type I error of 0.05). To allow for 132 dropouts, and enable subgroup analyses (trauma versus non-trauma), we intended to randomize 100 133 patients (25 patients for each stratum). 134
After randomization of 100 patients, an estimation of the baseline incidence of clear stomach in our 135 study population (without opening the randomization code) showed that 76% of patients had clear 136 stomach. Therefore, if erythromycin was 100% efficacious, the incidence of clear stomach with 137 placebo could not have been lower than 52% (76-50=26; 26/50=0.52), which was higher than we 138 expected. 36 Additionally, seeking an absolute increase of 50% in the incidence of clear stomach with 139 erythromycin had become illusory. Consequently, we revised the initial power calculation assuming a 140 baseline incidence of clear stomach of 50% but maintaining the aim of increasing that incidence to 141 80% with erythromycin. We randomized an additional 32 patients (16 patients per group) to reach 142 90% power to detect this smaller absolute risk difference (two-sided test, type I error 0.05). The 143 protocol was amended accordingly and approved by the institutional Ethics Committee and 144
SWISSMEDIC. 145
Statistical methods
146
The crude association between exposure to study treatment and primary endpoint was analyzed and 147 reported using odds ratios (OR) or risk ratios (RR) with 95% confidence intervals (CI). Crude 148 associations between all potential confounding variables and the primary endpoint in the placebo 149 group were analyzed separately. Each variable that was associated with the primary endpoint in the 150 placebo group was entered into a bivariate logistic regression model including study treatment and 151 primary endpoint. Crude and adjusted estimates were compared to assess the degree of potential included into a final multivariable model including all potential confounders. The impact of each variable on the fit of the model was tested using a likelihood ratio test. If the P-value of the test was 155 <0.1, the potential confounder was kept in the model, otherwise it was excluded. Interaction between 156 populations (trauma versus non-trauma) and study treatment was tested by introducing an interaction 157 term into the model; if the fit of the model to the data was increased by the interaction term, the results 158 were presented separately for the two strata. Sensitivity analyses using the alternative definition of Clear stomach, defined as no liquid and no solid, was diagnosed in 24 of 66 (36.4%) patients receiving Variables associated with the primary endpoint in the placebo group were study population (trauma vs 177 non-trauma), age, body weight, blood glucose, delay since last oral intake, and preoperative opiate use 178 (table 2) . In a bivariate logistic regression model, body weight and delay between last intake and 179 endoscopy changed the crude OR point estimate by more than 10%. When these variables were 180
included into the multivariate model, the association between erythromycin and clear stomach 181 increased (adjusted OR 2.96; 95%CI 1.28-6.83). Introducing an interaction term between population 182 (trauma versus non-trauma) and study treatment significantly increased the fit of the model to the data; 183 the impact of erythromycin was different according to the population studied. 184 compared with 4 (6.1%) and 2 (3.0%) patients receiving placebo (P>0.001). One patient in the 221 erythromycin group vomited before induction (Appendix C). There were no episodes of arrhythmia, 222 regurgitation of gastric contents or broncho-aspiration and no major adverse events. This is the first study showing that administration of erythromycin increases the proportion of clear 225 stomach among patients undergoing general anesthesia for emergency surgery. Depending on the 226 definition of clear stomach, the absolute risk reduction ranged from 17% to 24%, equivalent to a 227 number needed to treat of four to six patients to produce one completely cleared stomach. 228
Subgroup analyses: trauma versus non-trauma patients
Erythromycin also decreased acidity of stomach liquid. This might be related to erythromycin's 229 inhibitory effect on motilin receptor-mediated acid secretion. 34 Animal data indicate that a gastric pH 230 below 2.4 increases the risk of lung damage. 14,43 Also, when gastric fluid is effectively buffered, 231 higher volumes of aspirates are tolerated. 15, 44 We may assume that in surgical patients, erythromycin 232 will decrease the likelihood of significant lung tissue damage should broncho-aspiration occur despite 233 the premedication. 234
Erythromycin, through its prokinetic properties, more effectively clears stomachs from liquids than 235 solids. 28, 29 This may explain why the clearing effect of erythromycin appeared to be particularly strong 236 in non-trauma patients. In these patients, the delay between last oral intake and induction of anesthesia 237 was longer compared with trauma patients since they sometimes waited long periods with nil by 238 mouth until a diagnosis was confirmed and they were finally scheduled for surgery. In emergency 239 patients, liquid may accumulate in the stomach during starving. 240
Our study has strengths and weaknesses. One strength of our study is randomization, which ensures a 241 balanced distribution of potential known and unknown confounding factors and may explain why we 242 found only 2 variables (body weight, delay between last oral intake and endoscopy) influencing the 243 crude OR by more than 10%. It is possible that future studies may identify yet other factors associated 244
with gastric content and that may act as confounders despite the randomization (for instance, volume 245 of last meal, presence of gastroparesis). Another strength was the use of endoscopy to evaluate gastric 246 content. Estimation of volume of gastric content with aspiration through nasogastric tubes 247 underestimates the volume of residual gastric liquid. 45, 46 Also, endoscopy allows for visual inspection patients needing immediate emergency surgery. Most non-trauma patients suffered from acute 251 appendicitis or cholecystitis. As appendectomy is the most common emergency general surgical 252 procedure, 47 we may assume that our non-trauma cohort represented daily clinical practice in an 253 emergency center and that our results are likely to be representative of this population. However, 254 trauma patients had a low median Injury Severity Score indicating mostly minor trauma. Secondly, we 255 tested a single erythromycin regimen only. Erythromycin 1.5 mg kg -1 enhanced fasting gastric tone, 256 but 3.0 mg kg -1 , as in our trial, reduced the duration of meal-induced relaxation. 22, 48, 49 In a dose finding 257 study, 3.0 mg kg -1 was the most effective regimen to enhance gastric emptying in healthy subjects with 258 a reasonable averse effect profile. In surgical patients, no dose finding study has been performed so 259 far. It remains unknown whether higher doses would further increase efficacy or if smaller doses, 260 which may have a better adverse effect profile, are still efficacious. Thirdly, it might be argued that 261 erythromycin should be given earlier. After administration of erythromycin, half times of gastric 262 emptying after a solid meal were reported to be between 40 minutes 29 and 160 minutes. 28 Fourthly, our 263 choice of the primary endpoint may be debated. Clear stomach is a surrogate endpoint as only the 264 prevention of broncho-aspiration is of clinical relevance. There were no episodes of regurgitation or 265 broncho-aspiration. However, our study was not powered to quantify these more severe, but much less 266 frequent, events, and it seems impossible for patients who have no liquid and no solid at all in their 267 stomach to regurgitate, and subsequently aspirate gastric content into their lungs. Fithly, stomach 268 content at the end of surgery remained unknown. Gastric liquid may be secreted during surgery and 269 broncho-aspirated at extubation. However, prokinetic properties of erythromycin persist up to two 270 hours in the fed state. 50,51 Whether pre-treatment with erythromycin decreases the risk of perioperative 271 broncho-aspiration, and thus of pulmonary complications, in non-fasted patients undergoing 272 emergency surgery, remains to be formally shown. Finally, we did not investigate the occurrence of 273 postoperative infection. As with all macrolide antibiotics, induction of bacterial resistance remains a 274 concern. We believe that this concern remained theoretical. We gave a single dose only of unlikely that these drug-related adverse effects prevent clinicians from premedicating emergency 278 patients with erythromycin. A longer administration time is likely to reduce these risks as they 279 correlate with plasma concentrations of erythromycin. 52 There were no allergic reactions or episodes 280 of symptomatic cardiac arrhythmia; postoperative electrocardiograms were not performed 281 systematically. These results are in accordance with other single dose erythromycin studies. 33, 36, 53 In 282 elderly, co-prescription of erythromycin with a statin metabolized through CYP3A4 was shown to 283 increase statin toxicity. 54 It remains unclear, whether these data may be extrapolated to our study. Data are median (interquartile range) or number (%). The body-mass index is the weight in kilograms divided by the square of the height in meters. Pain and glycemia were measured at arrival in the operating room. Volumes are total volumes of liquids with or without solids. In each subgroup, patients are listed according to decreasing volumes. In the placebo group, non-trauma stratum, patient N° 1 had a residual volume of 900 ml.
